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Introduction: We measured duration mismatch negativity (dMMN), P3a, and reorienting
negativity (RON) in subjects with at-risk mental state (ARMS), patients with first-episode
or chronic schizophrenia, and healthy volunteers. The main interest was to determine if
these event-related potentials provide a biomarker associated with progression to overt
schizophrenia in ARMS subjects.
Methods: Nineteen ARMS subjects meeting the criteria of the Comprehensive Assess-
ment of ARMS, 38 patients with schizophrenia (19 first-episode and 19 chronic), and 19
healthy controls participated in the study. dMMN, P3a, and RON were measured with an
auditory odd-ball paradigm at baseline.
Results: During the follow-up period (2.2 years), 4 out of the 19 ARMS subjects transi-
tioned to schizophrenia (Converters) while 15 did not (non-Converters). dMMN amplitudes
of Converters were significantly smaller than those of non-Converters at frontal and central
electrodes before onset of illness. dMMN amplitudes of non-Converters did not differ from
those of healthy controls, while Converters showed significantly smaller dMMN amplitudes
compared to control subjects. RON amplitudes were also reduced at frontal and central
electrodes in subjects with schizophrenia, but not ARMS. Converter subjects tended to
show smaller RON amplitudes compared to non-Converters.
Conclusions: Our data confirm that diminished dMMN amplitudes provide a biomarker,
which is present before and after the development of psychosis. In this respect, RON
amplitudes may also be useful, as suggested for the first time based on longitudinal
observations.
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INTRODUCTION
Schizophrenia is a disorder characterized by positive symp-
toms (hallucination, delusion, thought disturbance, etc.), negative
symptoms (blunted affect, lack of volition, social withdrawal, etc.),
and a range of disturbances of cognitive functions (Heinrichs and
Zakzanis, 1998; Sumiyoshi et al., 2003; Harvey et al., 2004). In
particular, cognitive impairment of schizophrenia is considered to
largely determine the outcome of patients, including quality of life
and social function (Green, 1996).
Prolonged duration of untreated psychosis (DUP) has been
associated with poor long-term outcome, including work func-
tion, communication skills, and longer hospitalization (Loebel
et al., 1992; Edwards et al., 1999; Malla et al., 2004; Melle et al.,
2008; Yamazawa et al., 2008; Chang et al., 2011; Galderisi et al.,
2012). On the other hand, shorter DUP has been related with a
greater response to antipsychotic drugs in terms of symptoms and
quality of life (Perkins et al., 2005). For these reasons, early detec-
tion, intervention, and treatment of schizophrenia are needed. In
this context, it was reasonable that recent efforts have been directed
to subjects with “at-risk mental state (ARMS)” or “ultra-high-risk
patients” (McGorry et al., 2009).
The criteria for ARMS require that a young person aged
between 14 and 30 years being referred for mental health diffi-
culties met criteria for one or more of the following groups: (i)
attenuated psychotic symptoms group (APS): have experienced
sub-threshold, attenuated positive psychotic symptoms during the
past year; (ii) brief limited intermittent psychotic symptoms group
(BLIPS): have experienced episodes of frank psychotic symptoms
that have not lasted longer than a week and have spontaneously
abated; or (iii) trait and state risk factor group: have a first-degree
relative with a psychotic disorder or the identified client has a
schizotypal personality disorder, and they have experienced a sig-
nificant decrease in functioning during the previous year (Yung
et al., 1996; Broome et al., 2005).
To promote early diagnosis, objective markers, particularly
those based on brain morphology, neurophysiology, and neu-
ropsychology, have been reported to provide useful information
(Nakamura et al., 2004; Kawasaki et al., 2007b; Higuchi et al.,
2008, 2013b; Takahashi et al., 2011; Takayanagi et al., 2011; Lin
et al., 2012). Accordingly, event-related potentials (ERPs) have
been suggested to provide a biomarker for cognitive impairment
of schizophrenia.
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P300 (P3a and P3b) and mismatch negativity (MMN) have
been widely used for this purpose. Specifically, patients with
schizophrenia have been reported to show smaller P300 ampli-
tudes compared with normal control subjects (Roth et al., 1980;
Kawasaki et al., 1997; Bruder et al., 1998). Also, P300 amplitudes
have been shown to be reduced in subjects with ARMS (Ozgurdal
et al., 2008). On the other hand, P300 is affected by various fac-
tors, including medication (Umbricht et al., 1998; Higuchi et al.,
2008, 2013a; Sumiyoshi et al., 2009), suggesting the utility as a state
marker of psychotic disorders.
Mismatch negativity is another component of ERPs generated
in response to occasional variations (e.g., duration, frequency,
intensity) of acoustic stimuli, which occurs about 100–200 ms after
the onset of deviant stimulation, with peak amplitudes at fronto-
central leads (Naatanen et al., 2007, 2012). MMN amplitudes have
been suggested to reflect pre-attentive cognitive operations, and
decreased in patients with schizophrenia, as indicated by a recent
meta-analysis reporting a large effect size (Umbricht and Krljes,
2005). Unlike the case with P300, MMN amplitudes are generally
not affected by psychotropic drugs, for example, benzodiazepines
(Kasai et al., 2002) and dopamine antagonists (Leung et al., 2007).
For these reasons, MMN is considered to provide a trait marker
for schizophrenia.
Duration mismatch negativity (dMMN) amplitudes have been
shown to be reduced already in the prodromal stage of the illness
(Bodatsch et al., 2011; Jahshan et al., 2012; Shaikh et al., 2012;
Higuchi et al., 2013b). Furthermore, smaller dMMN amplitudes
have been reported in subjects with ARMS who later converted
to overt psychosis, compared to those who did not (Shaikh et al.,
2012; Higuchi et al., 2013b). Thus, reduced dMMN amplitudes are
regarded to predict conversion to schizophrenia in at-risk subjects
(Sumiyoshi et al., 2013).
P3a is a positive waveform that appears following MMN, i.e.,
between 250 and 300 ms after the presentation of stimuli. Its
amplitudes are largest at fronto-central electrodes. The P3a com-
ponent is assumed to reflect a pre-attentive index of deviance
detection, and represent the involuntary capture of attention
(Friedman et al., 2001).
A negative activity reflecting attentional “re”-orienting follows
P3a. This component is referred to as reorienting negativity (RON)
(Schroger and Wolff, 1998), which peaks at latencies between 400
and 600 ms, and is centered on fronto-central electrodes (Schroger
and Wolff, 1998; Otten et al., 2000; Schroger et al., 2000). The
MMN/P3a/RON complex has been shown to provide a neurophys-
iological index of the cascade of three main processes involved in
involuntary attention controls (i.e., automatic change detection,
orienting of attention, and reorienting of attention), following
deviant stimuli (Berti et al., 2004; Horvath et al., 2008).
Investigations into this series of ERP components should pro-
vide further insights into cognitive disturbances in schizophrenia
spectrum disorders, which have not been satisfactorily addressed.
Specifically, there is little information about the RON in schizo-
phrenia spectrum disorders. Jahshan et al. (2012) measured the
amplitudes of MMN, P3a, and RON complex, and found reduc-
tions of these parameters in schizophrenia patients. Also, ampli-
tudes of MMN and P3a, but not RON were diminished in indi-
viduals at-risk for psychosis. In spite of the above cross-sectional
study, further work is needed to test the utility of the ERP com-
plex for predicting progression to schizophrenia in vulnerable
individuals.
In this study, we measured dMMN, P3a, and RON ampli-
tudes in subjects with ARMS, first-episode schizophrenia (FES),
or chronic phase of the illness. These data were compared with
those of normal control subjects. We also attempted to determine
if these ERP parameters would predict later progression to schizo-
phrenia in ARMS subjects by means of longitudinal observations.
Specifically, preliminary data are provided on the evaluation of
RON in relation to transition to overt schizophrenia in vulnerable
subjects.
MATERIALS AND METHODS
PARTICIPANTS
Diagnosis was made based on the Structured Clinical Interview
for DSM-IV (SCID) for schizophrenia and the Comprehensive
Assessment of At-Risk Mental State (CAARMS) for ARMS (Yung
et al., 2005), by experienced psychiatrists. Most of these sub-
jects were referred from Psychiatric Health and Welfare Center
of Toyama (PHWCT), as previously described (Higuchi et al.,
2013b). Nineteen ARMS subjects followed at the University of
Toyama Hospital participated in this study [male/female= 9/10;
mean (SD) age= 19.4 (3.6) years]. Thirty-eight schizophrenia
patients also participated in this study. Patients with duration of
illness <2 years were defined as FES [n= 19; male/female= 9/10;
mean (SD) age= 22.8 (5.2) years], while those with duration of
illness 2 years or longer were defined as chronic schizophrenia
(CS) [n= 19; male/female= 9/10; mean (SD) age= 22.9 (3.6)
years] (Higuchi et al., 2013b). The patients who allocated “first
episode” are defined “single psychotic episode” and “duration of
illness is <2 years.” CS patients are defined “duration of illness
is more than 2 years.” Even if patients experienced only one psy-
chotic episode, they allocated to CS group. We recruited normal
control subjects from the community by advertisements. They
are healthy volunteers [n= 19; male/female= 9/10; mean (SD)
age= 19.4 (2.5) years] without any personal history of psychiatric
illnesses, including schizophrenia or other psychotic disorders. All
participants were right-handed. A psychiatric and treatment his-
tory was obtained from the subjects, families, and medical records.
Subjects with a current history of substance abuse or dependence,
seizure, or head injury were excluded from the study. Eligible
patients had a complete physical examination and standard lab-
oratory testing was normal. As clinical assessments, the Scale for
the Assessment of Positive Symptoms (SAPS) and the Scale for
the Assessment of Negative Symptoms (SANS) (Andreasen, 1990)
were administered by an experienced psychiatrist. Demographic
data at baseline evaluation are shown in Table 1A.
At-risk mental state subjects were followed-up at the hospital.
Four out of the 19 ARMS subjects transitioned to schizophre-
nia during the observation period. When DSM-IV criteria were
met, e.g., auditory hallucinations persisted or any delusion (for
example, disturbance of the self) clearly observed, the subject was
regarded to have converted to schizophrenia (Converters; Conv).
Subjects who did not develop psychosis were defined as non-
converters (Non-C). The average observation period for Non-C
subjects was 2.2± 1.5 years.
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Table 1 | (A) Demographic and clinical data; (B) ERP data.
(A) Healthy controls
(n=19)
ARMS
(n=19)
First-episode schizophrenia
(n=19)
Chronic schizophrenia
(n=19)
Group comparison
Male/female 9/10 9/10 9/10 9/10 n.s.
Age (years) 19.4 (2.5) 19.4 (3.6) 22.8 (5.2) 22.9 (3.6) F (3,74)=4.94, p=0.004
Age of onset (years) – – 22.2 (5.2) 17.9 (3.9) p=0.007
Duration of illness (years) – – 0.7 (0.6) 5.0 (2.3) –
Drug dosea – 0.1 (0.4) 1.7 (2.0) 3.7 (4.2) F (2,56)=8.54, p=0.001
SAPS – 17.3 (7.4) 27.0 (16.9) 19.2 (18.0) F (2,56)=2.29, p=0.11
SANS – 60.8 (24.3) 60.6 (27.2) 53.3 (22.9) F (2,56)=0.52, p=0.59
(B) Healthy controls
(n=19)
ARMS
(n=19)
First-episode schizophrenia
(n=19)
Chronic schizophrenia
(n=19)
Analyze of variance
(df=3,75), group effect
F p
dMMN amplitude (µV)
F3 −6.9 (1.7) −6.2 (2.0) −5.0 (1.8) −4.6 (1.0) 7.505 <0.001**
F4 −7.5 (1.4) −6.5 (2.2) −5.2 (2.1) −4.6 (2.0) 7.767 <0.001**
Fz −7.4 (1.4) −6.5 (2.0) −5.4 (1.9) −4.8 (1.5) 8.322 <0.001**
Cz −6.0 (1.4) −5.6 (2.1) −4.8 (1.9) −3.7 (0.9) 6.831 <0.001**
Pz −4.2 (1.4) −4.5 (4.0) −3.3 (1.4) −2.2 (0.9) 6.240 0.001**
dMMN latency (ms)
F3 167.3 (15.1) 172.1 (17.5) 173.0 (23.0) 177.8 (30.7) 0.702 0.55
F4 169.1 (15.4) 175.8 (18.3) 172.5 (19.7) 176.6 (24.0) 0.404 0.75
Fz 172.2 (15.6) 177.3 (12.6) 173.0 (19.1) 176.8 (25.6) 0.364 0.77
Cz 168.4 (14.8) 182.3 (18.7) 174.6 (16.7) 177.6 (26.2) 1.675 0.18
Pz 173.0 (15.8) 188.6 (24.4) 178.3 (17.4) 174.8 (30.7) 1.753 0.16
P3a amplitude (µV)
F3 1.6 (1.8) 1.1 (1.4) 1.3 (2.2) 1.5 (1.3) 0.277 0.84
F4 1.4 (2.3) 1.2 (1.8) 1.6 (2.1) 1.4 (1.4) 0.110 0.95
Fz 2.0 (2.3) 1.7 (1.5) 1.7 (2.2) 1.7 (1.1) 0.179 0.91
Cz 2.4 (2.4) 2.1 (1.6) 2.5 (2.1) 2.1 (1.4) 0.209 0.89
Pz 2.0 (2.2) 1.8 (1.4) 2.3 (1.8) 1.8 (1.3) 0.408 0.74
P3a latency (ms)
F3 255.6 (23.5) 265.2 (25.0) 264.2 (28.3) 262.8 (23.0) 0.395 0.75
F4 256.9 (20.2) 269.7 (28.0) 262.9 (31.1) 255.2 (30.8) 0.755 0.52
Fz 254.6 (21.5) 268.7 (28.8) 261.8 (30.9) 262.3 (22.3) 0.314 0.81
Cz 255.1 (21.7) 266.0 (25.9) 254.8 (28.7) 262.2 (22.9) 0.509 0.67
Pz 255.7 (19.8) 272.2 (27.2) 254.7 (27.6) 261.4 (19.7) 0.359 0.78
RON amplitude (µV)
F3 −4.4 (1.7) −4.1 (1.7) −3.5 (1.3) −3.3 (1.3) 2.320 0.08
F4 −5.2 (1.8) −4.2 (1.5) −3.6 (1.7) −3.4 (1.6) 4.191 0.009**
Fz −5.1 (1.6) −4.2 (1.8) −3.9 (1.4) −3.4 (1.7) 3.143 0.03*
Cz −4.3 (1.9) −3.8 (2.1) −3.6 (1.6) −3.2 (1.6) 1.143 0.33
Pz −3.1 (1.8) −2.7 (1.7) −2.5 (1.5) −2.6 (1.6) 0.391 0.76
RON latency (ms)
F3 396.3 (51.8) 380.7 (49.4) 395.0 (42.7) 389.0 (52.6) 0.395 0.75
F4 392.7 (53.9) 404.0 (54.1) 409.1 (53.1) 385.4 (53.8) 0.755 0.52
Fz 396.2 (50.2) 397.2 (46.8) 409.3 (40.9) 397.7 (53.3) 0.314 0.81
Cz 401.2 (39.0) 398.3 (44.4) 412.5 (40.9) 397.0 (47.4) 0.509 0.67
Pz 409.5 (48.2) 401.7 (45.7) 411.7 (40.7) 397.4 (58.2) 0.359 0.78
Values represent mean (SD).
aRisperidone equivalent (mg/day), ARMS, at-risk mental state; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative
Symptoms.
Values represent mean (SD). ARMS, at-risk mental state.
*p<0.05, **p<0.01.
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ELECTROENCEPHALOGRAM RECORDING
Electroencephalograms (EEGs) were recorded based on the pre-
vious report from our laboratory (Sumiyoshi et al., 2006, 2009;
Kawasaki et al., 2007a; Higuchi et al., 2008, 2010, 2013a,b; Itoh
et al., 2011).
A 32-channel DC-amplifier (EEG-2100 version 2.22J, Nihon
Kohden Corp., Tokyo, Japan) was used. Recordings were per-
formed using an electro cap (Electrocap Inc., Eaton, OH) in a
sound-attenuated room. Data were collected with a sampling rate
of 500 Hz. EEG data were collected from 29 scalp electrodes (Fp1,
Fp2, F3, F4, F7, F8, FC3, FC4, C3, C4, T3, T4, CP3, CP4, TP7, TP8,
P3, P4, T5, T6, O1, O2, FPz, Fz, FCz, Cz, CPz, Pz, and Oz according
to the extended International 10–20 system). All electrodes were
referred to the average amplitude of the ear electrodes (band-
width= 0.53–120 Hz, 60 Hz notch filter). Electrode impedance
was <5 kΩ.
Measurements of dMMN/P3a/RON complex were based on
our previous report (Higuchi et al., 2010). One-thousand auditory
stimuli were delivered binaurally through headphones with inter-
stimulus intervals 500 ms. Standard/target tones of 50/100 ms
duration were randomly presented with the presentation proba-
bility of 0.9/0.1. All tones were 60 dB, 1000 Hz, and with a rise–fall
time of 10 ms. The subjects were requested to watch silent anima-
tion movie (Tom and Jerry) and pay attention to the monitor and
ignore the tones.
Averaging of ERP waves and related procedures were performed
using Vital Tracer and EPLYZER II software (Kissei Comtec, Co.
Ltd., Nagano, Japan). Epochs were 600 ms, including a 100 ms pre-
stimulus baseline. Eye movement artifacts (blinks and eye move-
ments) were manually rejected. MMN waveforms were obtained
by subtract standard waveforms from target ones. MMN, P3a, and
RON peaks were identified within the 150–250 ms (minus peak),
200–350 ms (plus peak), and 250–500 ms (minus peak) search
windows, respectively.
STATISTICAL METHODS
Statistical analyses were performed using the Statistical Pack-
age for Social Sciences (SPSS) version 20 (SPSS Japan Inc.,
Tokyo, Japan). We performed comparison of age between four
groups (HC, ARMS, FES, and CS) by one-way analysis of
variance. Onset age and duration of illness of two schizo-
phrenia groups (first-episode and chronic) were compared by
independent t -test. Drug dose, SAPS, and SANS score among
three groups (ARMS, FES, and CS) were analyzed by one-way
ANOVA.
Event-related potential amplitudes and latencies were mea-
sured and analyzed at five electrodes; three from frontal lobe (F3,
F4, and Fz), and two from midline (Cz and Pz). They are typical
electrodes that commonly used on ERP studies. MMN ampli-
tudes are generally largest at frontal electrodes, so we choose three
electrodes from frontal lobe. Moreover, grand average waveforms
(Figures 1 and 3) and scatterplots (Figures 2 and 4) were drawn
and analyzed by Fz lead as a representative of electrodes because
amplitudes ERPs of Fz were largest. Laterality of ERPs was ana-
lyzed by F3/F4 comparison as we performed in previous report
(Higuchi et al., 2008), but there were no difference in this study
(data not shown).
FIGURE 1 | Duration mismatch negativity (dMMN), P3a, and
reorienting negativity (RON) complex waveforms at Fz for all subjects.
Waveforms are presented for healthy controls (HC, blue line), at-risk mental
state (ARMS, red line), first-episode schizophrenia (FES, light green line),
and chronic schizophrenia (CS, dark green line).
Two-way ANOVA was conducted on amplitudes and latencies
of dMMN, P3a, and RON, with “Stage” (HC, ARMS, FES, and CS)
and “Lead” (F3, F4, Fz, Cz, and Pz) as fixed factors. Main effects
(of Stage and Lead) were described on Table 1B (significant dif-
ferences were seen in all leads of dMMN amplitude and F4/Fz of
RON amplitude). The Stage-by-Lead interactions on amplitudes
(dMMN, F = 1.172, p= 0.30; P3a, F = 0.511, p= 0.90; RON,
F = 1.024, p= 0.42) and latencies (dMMN, F = 1.254, p= 0.246;
P3a, F = 1.475, p= 0.13; RON, F = 0.516, p= 0.904) were not
significant.
Gender difference between Conv and Non-C were analyzed
by Chi-square test. Other factors (age, drug dose, SAPS, SANS,
ERP amplitude, and latency) of them were calculated by indepen-
dent t -test. All analyses of variance were corrected by Bonferroni
correction.
Correlations of symptoms and ERP amplitudes were performed
by Pearson product–moment correlation coefficient. SAPS scores
(hallucinations, delusions, bizarre behavior, and positive formal
thought disorder) and SANS scores (affective flattening/blunting,
alogia, avolition-apathy, anhedonia-asociality, and attention) were
used.
Raters were not informed of subjects’ profiles and diagnosis.
RESULTS
SUBJECTS’ PROFILE
Demographic and clinical data of participants are shown in
Tables 1A and 2. There was significant group difference in age
[F(3,74)= 4.94,p= 0.004,ANOVA],and Conv subjects were older
than Non-C in age (p= 0.009, t -test). Male/female ratio did not
differ between of Conv. and Non-C groups [χ2= 2.47, p= 0.3,
Chi-square test].
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FIGURE 2 | Distribution of amplitudes of duration mismatch negativity [dMMN; (A)] and reorienting negativity [RON; (B)] at Fz for all subjects. Data
are presented for healthy controls (HC), ARMS, first-episode schizophrenia (FES), and chronic schizophrenia (CS). *p<0.05, **p<0.01.
FIGURE 3 | Duration mismatch negativity (dMMN), P3a, and
reorienting negativity (RON) complex waveforms at the Fz lead.
Waveforms are presented for healthy controls (blue line), ARMS Converters
(Conv), and non-Converter (Non-C) (black lines), and FES (green line).
Sixteen out of 19 ARMS subjects were not taking any med-
ication, while three were prescribed a small dose of risperidone
(1.5 mg/day), aripiprazole (3 mg/day), and sulpiride (150 mg/day),
respectively, for acute psychosis episodes (sometimes with strong
agitation), based on the criteria of International Early Psychosis
Association Writing Group (2005). MMN recordings for these sub-
jects were conducted immediately after medications were started
(9, 15, and 27 days). Two out of the three subjects subsequently
developed schizophrenia. Thirteen out of 19 FES patients and
15 out of 19 CS patients were taking antipsychotic medica-
tions. There were no significant differences among ARMS, FES,
and CS groups in SAPS [F(2,56)= 2.29, p= 0.11, ANOVA] and
SANS [F(2,56)= 0.52,p= 0.59,ANOVA] scores. Conv and Non-C
groups did not differ in the SAPS and SANS scores at baseline
(p= 0.08, 0.24, respectively, t -test).
COMPARISONS OF ERP BETWEEN HEALTHY CONTROLS VS. ARMS VS.
SCHIZOPHRENIA
Grand average ERP waveforms in the Fz lead following deviant
stimulation are shown in Figure 1. Scatterplots of dMMN and
RON amplitudes at Fz lead are shown in Figures 2A,B, respec-
tively. P3a did not show any statistical differences so we skipped
making scatterplot of P3a. ARMS subjects showed relatively
smaller dMMN amplitudes at Fz (−6.5± 2.0µV) compared to
those of healthy control subjects (−7.4± 1.4µV), which was
not statistically significant (p= 0.13, t -test). On the other hand,
FES group showed significantly smaller dMMN amplitudes at
Fz (−5.4± 1.9µV) compared to healthy control (p= 0.001, t -
test). Patients with CS showed greater amplitude reductions at
Fz (−4.8± 1.5µV) compared to healthy controls (p= 0.000004,
t -test).
At-risk mental state subjects showed relatively smaller
RON amplitudes at Fz (−4.2± 1.8µV) than healthy controls
(−5.1± 1.6µV), which was not significant (p= 0.15, t -test).
On the other hand, FES group showed significantly smaller
RON amplitudes at Fz (−3.9± 1.4µV, p= 0.02). Patients with
CS also elicited significantly smaller RON amplitudes at Fz
(−3.4± 1.7µV) compared to healthy controls (p= 0.005, t -test).
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FIGURE 4 | Distribution of amplitudes of duration mismatch negativity [dMMN; (A)] and reorienting negativity [RON, (B)] at Fz for ARMS. Data are
presented Converters (Conv) and Non-Converter (Non-C). *p<0.05.
Latencies of dMMN, P3a, and RON at any electrodes did not
differ among the four groups (see Table 1B).
COMPARISONS BETWEEN CONVERTERS VS. NON-CONVERTERS
Grand average ERP waveforms are shown in Figure 3. Scatter-
plots of dMMN and RON amplitudes at Fz lead are shown in
Figures 4A,B, respectively. P3a did not show any statistical differ-
ences so we skipped making scatterplot of P3a. Waveforms of Conv
group were similar to those of FES patients. By contrast, wave-
forms of Non-C subjects resembled to those of healthy controls.
Conv subjects showed significantly smaller dMMN amplitudes at
Fz and Cz electrodes compared with Non-C subjects (p= 0.03,
0.05 by t -test, respectively, Table 2). On the other hand, ampli-
tudes of Non-C did not differ from those of HC (p= 0.51 at Fz,
t -test, data not shown) and there was no significant difference in
dMMN amplitudes between Conv and FES subjects (p= 0.44 at
Fz, t -test, data not shown). In other electrode of Non-C vs. HC
and Conv vs. FES comparisons, differences were smaller and did
not reach significance.
Conv subjects tended to show smaller RON amplitudes com-
pared to those of Non-C subjects at Fz and F4 electrodes (p= 0.08,
p= 0.08 by t -test, respectively, Table 2). Also, HC group showed
relatively larger RON amplitudes at Fz lead compared to Conv sub-
jects, which did not reach significant level (p= 0.08, t -test, data
not shown). No significant differences were found at any electrode
between FES vs Non-C groups (data not shown).
Latencies of dMMN, P3a, and RON at any electrodes did not
differ between Conv and Non-C groups (see Table 2).
RELATIONSHIP BETWEEN SYMPTOMS AND ERPs
We evaluated the correlations between dMMN, P3a, and RON
amplitudes and symptoms (SAPS and SANS) in patients (schizo-
phrenia and ARMS, n= 57).
Data are shown in Table 3. There were significant correlation
between attention disorder score (SANS) and dMMN amplitude at
Fz and F3 lead (r = 0.317; p= 0.025, r = 0.290, p= 0.041, respec-
tively, by Pearson’s correlation). Moreover, there were significant
correlation between positive formal thought disorder score (SAPS)
and RON amplitude at Fz and F3 lead (r = 0.280; p= 0.049,
r = 0.346, p= 0.014, respectively, by Pearson’s correlation). Thus,
reduction of ERPs was correlated with severity of some symptoms.
DISCUSSION
Duration mismatch negativity amplitudes at frontal and central
leads were reduced in ARMS subjects who later converted to
overt schizophrenia in comparison with non-converters and nor-
mal subjects, consistent with previous reports (Bodatsch et al.,
2011; Shaikh et al., 2012; Higuchi et al., 2013b). Specifically,
the current data from gender matched subjects across groups
(Table 1) confirmed previous observations in patients with vari-
able demographic backgrounds (Bodatsch et al., 2011; Shaikh et al.,
2012; Higuchi et al., 2013b). Importantly, this study is the first
to suggest that RON provides a marker for the progression to
overt schizophrenia in subjects with ARMS, based on longitudinal
observations.
Three out of 4 Conv, 7 out of 15 Non-C, 7 out of 19 FES, 5 out
of 19 CS, and 9 out of 19 HC subjects overlapped with subjects in
our previous report (Higuchi et al., 2013b). We selected subjects
for the current study, according to the following considerations;
(1) ARMS subjects with a longer followed-up period, (2) gender-
match between HC and schizophrenia patients, (3) younger HC
and schizophrenia patients than those used in the previous study.
The current one used a longer observation period, and was gender-
matched across groups with less variation in age. According to a
previous report (Yung et al., 2003), 10–40% of ARMS subjects
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Table 2 | Comparison between converters and non-converters of
ARMS subjects.
ARMS (n=19) Group
comparison (p)
Non-C (n=15) Conv (n=4)
Male/female 7/8 3/1 χ2=2.47, p=0.3
Age (years) 18.3 (2.2) 23.4 (4.9) 0.009
Drug dosea 0.1 (0.2) 0.4 (0.6) 0.12
SAPS 15.3 (7.0) 22.7 (5.8) 0.08
SANS 56.9 (26.3) 73.7 (9.6) 0.24
dMMN amplitude (µV)
F3 −6.5 (2.1) −4.9 (0.6) 0.16
F4 −7.0 (2.2) −4.6 (0.9) 0.06
Fz −7.0 (2.0) −4.7 (1.0) 0.03*
Cz −6.1 (2.1) −3.7 (0.6) 0.05*
Pz −3.8 (2.1) −3.0 (0.4) 0.48
dMMN latency (ms)
F3 169.3 (18.5) 182.5 (8.2) 0.19
F4 174.2 (20.1) 182.0 (8.1) 0.47
Fz 176.2 (13.6) 181.5 (8.2) 0.47
Cz 180.2 (19.7) 190.0 (13.3) 0.37
Pz 186.8 (25.2) 195.5 (23.2) 0.54
P3a amplitude (µV)
F3 1.0 (1.4) 1.5 (1.1) 0.60
F4 1.2 (2.0) 1.2 (1.1) 0.96
Fz 1.6 (1.5) 2.0 (1.2) 0.67
Cz 1.9 (1.6) 2.6 (1.4) 0.47
Pz 2.0 (1.4) 0.7 (0.8) 0.10
P3a latency (ms)
F3 264.7 (27.9) 267.0 (27.9) 0.88
F4 270.1 (31.3) 268.0 (31.3) 0.90
Fz 269.1 (32.3) 267.5 (32.3) 0.93
Cz 264.8 (28.8) 270.5 (28.8) 0.71
Pz 268.4 (29.0) 286.5 (29.0) 0.26
RON amplitude (µV)
F3 −4.3 (1.7) −3.1 (1.2) 0.20
F4 −4.5 (1.4) −3.1 (1.0) 0.08
Fz −4.6 (1.6) −2.8 (2.1) 0.08
Cz −4.2 (2.1) −2.5 (1.6) 0.16
Pz −2.7 (1.8) −2.7 (1.1) 0.97
RON latency (ms)
F3 388.0 (51.3) 353.5 (33.4) 0.22
F4 403.6 (51.4) 405.5 (72.0) 0.95
Fz 391.3 (44.8) 419.5 (53.8) 0.29
Cz 399.3 (48.6) 394.5 (28.4) 0.85
Pz 401.8 (51.3) 401.2 (33.4) 0.98
Values represent mean (SD).
aRisperidone equivalent (mg/day).
ARMS, at-risk mental state; Non-C., ARMS non-Converters; Conv., ARMS Con-
verters; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for
the Assessment of Negative Symptoms.
*p<0.05.
later developed schizophrenia, consistent with our observations
that 21.0% progressed to the illness.
ARMS subjects as a whole have been reported to demonstrate
reduced dMMN amplitudes, but with a lesser degree compared
to patients with overt schizophrenia (Bodatsch et al., 2011; Atkin-
son et al., 2012; Jahshan et al., 2012), consistent with the present
results (Figure 1). On the other hand, the current data may be
partly different from our previous observations indicating the
lack of difference in dMMN amplitudes between ARMS sub-
jects as whole and healthy controls (Higuchi et al., 2013b). One
of the reasons for this discrepancy may include the difference
in age and gender ratio. In fact, as previous reports indicate
ERPs amplitudes gradually decrease by age, and male subjects
show relatively smaller amplitudes than female because of the
difference in skull thickness (Ikezawa et al., 2008; Matsubayashi
et al., 2008; Naatanen et al., 2012). Another confounding fac-
tor may include the observation periods for follow-up. While
our previous report (Higuchi et al., 2013b) employed a relatively
short period (mean± SD= 1.6± 0.8 years for non-converters),
the present study used a longer period (2.2± 1.5 years), similar
to those in the literature.
Compared to Non-C, Conv subjects elicited significantly
smaller dMMN amplitudes at F4 and Fz leads (Table 2). These
observations suggest the ability of dMMN amplitudes to differ-
entiate between high-risk individuals who later progress to schiz-
ophrenia and those who do not, as has been suggested (Higuchi
et al., 2013b; Sumiyoshi et al., 2013).
Little information has been available about the feature of RON
in schizophrenia. In this study, RON amplitudes of ARMS subjects
as a whole were not different from those of HC subjects, while FES
and CS group showed significantly smaller RON amplitudes at Fz
and F4 leads compared to the HC group. This finding is consistent
with observations by Jahshan et al. (2012). As the results of the
current study suggest that RON amplitudes may decrease accord-
ing to progression of clinical stages of schizophrenia (Table 1B;
Figure 1), they may provide an intermediate phenotype of the
illness.
Importantly, RON amplitudes of Conv subjects tended to be
smaller than those of Non-C at the Fz and F4 leads (Figure 4). The
failure to reach statistical significance may be due to the fact that
RON waveforms are not stable and smaller compared to dMMN
waveforms. Future investigations with a larger number of subjects
would be desirable to determine if the combined measurement
of RON and dMMN would further facilitate early detection of
schizophrenia.
P3a amplitudes were barely detectable in this study (Figures 1
and 3). These amplitudes have been reported to be decreased in
schizophrenia and ARMS (Friedman et al., 2001; Jahshan et al.,
2012; Mondragon-Maya et al., 2013; Nagai et al., 2013). Variations
of P3a amplitudes may be large, due, probably, to the difference in
measurement.
Limitations of this study include the small sample number,
especially in ARMS (n= 19) and Conv subjects (n= 4). Accord-
ing to the power analysis, at least 26 patients are needed to obtain
adequate effect size (i.e., 0.6). Investigations with a larger number
of patients will make the data more satisfactory. Second, sig-
nificant age difference was seen in the ARMS vs. HC and FES
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Table 3 | ERP amplitudes and symptoms.
SAPS
Hallucinations Delusions Bizarre
behavior
Positive formal
thought disorder
r p r p r p r p
dMMN amplitude (µV)
F3 0.039 0.786 0.011 0.938 −0.122 0.398 0.086 0.552
F4 0.071 0.625 0.066 0.648 −0.131 0.365 0.076 0.599
Fz 0.021 0.884 −0.016 0.910 −0.199 0.166 0.090 0.536
Cz −0.021 0.888 −0.036 0.805 −0.108 0.457 0.056 0.697
Pz −0.163 0.258 −0.178 0.216 −0.225 0.117 −0.069 0.636
P3a amplitude (µV)
F3 −0.148 0.305 −0.188 0.192 −0.188 0.191 −0.036 0.802
F4 −0.075 0.605 −0.190 0.187 −0.256 0.073 0.029 0.842
Fz −0.191 0.185 −0.181 0.209 −0.233 0.104 −0.008 0.956
Cz −0.149 0.302 −0.056 0.701 −0.213 0.138 0.020 0.891
Pz 0.022 0.879 0.046 0.753 −0.023 0.874 −0.117 0.417
RON amplitude (µV)
F3 0.014 0.926 −0.131 0.363 0.067 0.646 0.280 0.049*
F4 0.087 0.549 −0.092 0.523 −0.158 0.274 0.244 0.087
Fz −0.024 0.869 −0.109 0.450 −0.265 0.063 0.346 0.014*
Cz −0.033 0.818 −0.214 0.136 −0.081 0.578 0.151 0.295
Pz 0.002 0.990 −0.257 0.071 −0.025 0.861 0.022 0.881
SANS
Affective
flattening
Alogia Avolition-
apathy
Anhedonia-
asociality
Attention
r p r p r p r p r p
dMMN amplitude (µV)
F3 0.109 0.452 0.149 0.301 0.096 0.509 −0.102 0.483 0.317 0.025*
F4 0.142 0.325 0.122 0.399 0.016 0.910 −0.066 0.650 0.260 0.068
Fz 0.115 0.427 0.165 0.254 −0.014 0.923 −0.081 0.576 0.290 0.041*
Cz 0.060 0.680 0.147 0.307 0.117 0.420 0.050 0.730 0.262 0.066
Pz −0.041 0.778 0.066 0.650 0.122 0.400 −0.063 0.666 −0.007 0.963
P3a amplitude (µV)
F3 −0.029 0.843 −0.034 0.815 0.037 0.796 −0.037 0.796 0.130 0.368
F4 0.021 0.883 0.021 0.885 0.003 0.984 −0.102 0.480 0.148 0.306
Fz −0.043 0.767 0.032 0.823 −0.032 0.827 −0.090 0.533 0.101 0.487
Cz −0.066 0.649 −0.029 0.843 0.012 0.934 −0.010 0.943 0.112 0.441
Pz 0.063 0.662 −0.027 0.852 0.108 0.454 −0.046 0.753 0.032 0.827
RON amplitude (µV)
F3 −0.112 0.438 −0.111 0.441 −0.054 0.712 −0.215 0.134 −0.055 0.704
F4 0.022 0.882 0.039 0.788 −0.089 0.539 −0.103 0.475 −0.050 0.730
Fz −0.046 0.752 −0.017 0.905 −0.104 0.474 −0.073 0.617 −0.025 0.861
Cz 0.128 0.375 0.210 0.143 −0.040 0.781 0.002 0.988 −0.108 0.455
Pz 0.014 0.922 0.095 0.513 −0.123 0.393 −0.117 0.419 −0.242 0.090
SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms.
*p<0.05, r=Pearson product–moment correlation coefficient.
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vs. CS comparisons. Since part of ARMS subjects is regarded
as prodromal state of schizophrenia, it is natural that they are
mostly younger than schizophrenia patients. Therefore, adjust-
ment of age between FES/CS and ARMS subjects may increase
the number of certain type of schizophrenia, e.g., hebephrenic
type. Due to an effort to make the FES/CS groups more homoge-
neous, patients of these groups became somewhat older than the
ARMS group. Application of ANCOVA to 19 members may pro-
vide over-adjustment. Although MMN amplitudes are reduced
gradually by age, the decline is not substantial (−0.056µV/year
in schizophrenia and −0.079µV/year in healthy control) (Kiang
et al., 2009). ARMS/HC subjects are about 2.5 years younger than
FES/CS (Table 1). According to this formula, about 0.2µV ampli-
tude reduction may occur between these two. Differences in our
data presented (at Fz lead) were 1.1µV or greater (ARMS vs. FES
groups.), which was sufficiently large. Third, some ARMS subjects
and most schizophrenia patients were taking antipsychotic drugs,
which may be another limitation of the current study. Fourth, in
this study, we measured ERPs at baseline, and did not perform
follow-up measurements. Therefore, little information is available
about longitudinal data of ERPs parameters.
In conclusions, diminished amplitudes in dMMN/RON may
provide a biomarker that is present before and after the develop-
ment of psychosis. Our results should be interpreted with caution
before applying to the at-risk population, especially to avoid over-
diagnosis. Ideally, the combination with other cognitive modal-
ities, e.g., neuropsychological tests (Higuchi et al., 2013b), brain
morphology, and biochemical markers, would enhance the sensi-
tivity and specificity for early diagnosis. These efforts are expected
to help improve functional outcome in subjects with schizophrenia
and vulnerable individuals as well.
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